Women's infertility market set for slow growth due to upcoming patent expiries

2 September 2010

The global women's infertility market was valued at $1.42 billion in 2009 and is forecast to increase at a compound annual growth rate (CAGR) of 2% to reach $1.61 billion by 2017, in a new report from GlobalData.

The slow market growth is attributed to the patent expiry of the branded products such as AEterna Zentaris' Cetrotide (cetrorelix), and Merck Serono's Ovidrel (choriogonadotropin alfa for injection) in 2015. Some key branded products, such as Cetrotide, Merck Serono's Gonal-f (follitropin alfa), Crinone (progesterone gel), Ovidrel, Luveris (lutropin alfa for injection), and Pergoveris (follitropin alfa and lutropin alfa) and Organon's (now Merck & Co) Puregon (follitropin beta), are going to face a severe threat from generics as they approach patent expiry between 2010 and 2015.

Current treatment options cater to most of the market need

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK